Merdury Biopharmaceutical Corporation (6932) Stock Price & Analysis
6932 Stock Chart & Stats
- Day’s Range
- TWD 4.98 - TWD 5.28
- 52-Week Range
- TWD 4.71 - TWD 12.20
- Previous Close
- TWD 5.28
- Volume
- N/A
- Average Volume (3M)
- 370.20K
- Market Cap
- TWD 2.22B
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- TWD 136.49M
- Total Debt (Recent Filing)
- TWD 42.80M
- Price to Earnings (P/E)
- ―
- Beta
- 0.54
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6932 FAQ
What was Merdury Biopharmaceutical Corporation’s price range in the past 12 months?
What is Merdury Biopharmaceutical Corporation’s market cap?
When is Merdury Biopharmaceutical Corporation’s upcoming earnings report date?
Is Merdury Biopharmaceutical Corporation overvalued?
Does Merdury Biopharmaceutical Corporation pay dividends?
What is Merdury Biopharmaceutical Corporation’s EPS estimate?
How many shares outstanding does Merdury Biopharmaceutical Corporation have?
Which hedge fund is a major shareholder of Merdury Biopharmaceutical Corporation?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Merdury Biopharmaceutical Corporation
Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly boost the bioavailability of active pharmaceutical ingredients, leading to a reduction in required drug dosages and fewer adverse effects. Their development pipeline currently addresses a variety of ailments, such as erectile dysfunction, pulmonary hypertension, sleep disturbances, benign prostatic hyperplasia, angina, migraines, hypertension, and pain management.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yaoren Liang
- Employees
- 21
- Website
- merdury.com
- Address
- No. 653, Bannan Rd., New Taipei City, TP, 235030, TW
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |

